Low data variability

Our core ECG laboratory provides a centralised system for all our studies. High precision ECG acquisition in our clinic provides meaningful ECG analysis with a smaller sample size, making us the ideal choice for the integration of cardiac safety in FIH and MAD studies.

We are a leading publisher in cardiology and have publicly accessible credentials. We are proud of our integrity, our professional growth and experience in this field.

Learn more about our ECG Lab

Exceptional ECG generation

We undertake and analyse several cardiological assessments using state-of-the-art equipment to understand and explain abnormal ECG data obtained during a clinical study of a new chemical entity.

Learn more about our cardio analysis services

Experts in cardiac safety

Richmond Pharmacology’s Core ECG Laboratory team are based within St George’s Hospital Medical School, London and are made up of highly experienced cardiologists headed by Professor John Camm, a key opinion leader in TQT Trials.

Learn more about our expert cardiologists

Committed to patient safety through expert Pharmacovigilance

At Richmond Pharmacology, patient safety is at the heart of every clinical trial. Our dedicated Pharmacovigilance (PV) team ensures that all safety data are captured, assessed and reported in compliance with global regulatory standards.

Pharmacovigilance is the science of monitoring and preventing adverse effects. It safeguards trial participants, ensures regulators and sponsors can act on emerging data, and underpins confidence in new medicines.

Talk to an expert

Our approach

1

Recording and evaluation of all adverse events, including those unrelated to the trial

2

Rigorous review of serious adverse events by our safety team and Principal Investigators

3

Tailored processes depending on the complexity of the trial, always aligned with regulatory requirements

4

Ethical governance in line with international safety frameworks

5

Close collaboration with investigators, doctors and sponsors to ensure patient protection

Our offering

Our PV processes have been developed to the highest standards, ensuring no important safety event is missed.
Every adverse event is recorded, reviewed and reported.

Dedicated trial-specific PV systems

Tailored processes designed to match each trial’s complexity, ensuring all safety data are captured, assessed, and reported in alignment with regulatory requirements.

Comprehensive adverse event collection

Recording and evaluation of all adverse events, including those unrelated to the trial, to ensure no important safety event is missed.

Timely safety reporting

Rigorous review of serious adverse events by our safety team and Principal Investigators, with prompt reporting to sponsors, regulators, and ethics committees.

Signal detection and escalation

Proactive monitoring to identify emerging safety signals early, enabling timely escalation and action in line with international safety frameworks.

Oversight and safety governance

Close collaboration between investigators, doctors, and sponsors ensures ethical governance and participant protection throughout every stage of the study.

PV training for trial staff

Continuous pharmacovigilance training maintains compliance and awareness across all teams, supporting consistent adherence to global standards.

Commitment to Global Standards

Our Pharmacovigilance systems operate in full compliance with ICH Guidelines, CIOMS VI Working Group recommendations, and The Medicines for Human Use (Clinical Trials) Regulations.

These frameworks ensure that every aspect of our safety monitoring meets the highest global regulatory standards.

Expert Team

Our Pharmacovigilance team includes experienced Drug Safety Monitors, safety physicians and clinical staff. Working together with Doctors, they bring expertise in early-phase research and ensure the highest standards of participant safety and regulatory compliance.

Get in touch today

Latest news

Patient safety is not an afterthought. Explore our new infographic!

September 17, 2025
Patient safety is not an afterthought; it is the foundation of every clinical trial.
Read more

Events

JSCPT 2025

5 – 6 December 2025
Richmond Pharmacology will attend JSCPT 2025 in Tokyo, represented by their leadership team. Topics include early-phase studies, bridging studies between Europe and Asia, gene and RNA-based therapy development, and cross-border collaboration.
View event